Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1998 Sep;7(9):2033–2037. doi: 10.1002/pro.5560070920

Characterization of recombinant human cathepsin B expressed at high levels in baculovirus.

P M Steed 1, D Lasala 1, J Liebman 1, A Wigg 1, K Clark 1, A K Knap 1
PMCID: PMC2144170  PMID: 9761485

Abstract

The lysosomal cysteine protease cathepsin B has been studied intensely for many years because of its unique characteristics and its potential involvement in disease states. A reproducible, high yield expression system for active recombinant protein is key to biochemical and biophysical studies as well as rational drug design. Although several microbial and mammalian expression systems for recombinant human cathepsin B have been described, these have been limited by low or variable yields. Further, in some of these systems hyper-glycosylation of the enzyme near the active site affects its activity. We describe a baculovirus expression system and purification scheme that solve all of these problems. Yields of active, protected enzyme were reproducibly in excess of 25 mg/L. Since this protein was not hyper-glycosylated, it had greater activity than cathepsin B produced in yeast systems as indicated by a threefold increase in Kcat. In addition, the biophysical properties of the baculovirus-expressed cathepsin B, as measured by dynamic light scattering, were more amenable to crystallographic study since the data indicated proteins of more uniform size. Therefore, this system for the production of recombinant human cathepsin B constitutes a major improvement in both quantity and quality over those previously reported. Further, we demonstrate that the manner of expression and purification of this enzyme has profound effects on its kinetic and physical parameters.

Full Text

The Full Text of this article is available as a PDF (1.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronson N. N., Jr, Barrett A. J. The specificity of cathepsin B. Hydrolysis of glucagon at the C-terminus by a peptidyldipeptidase mechanism. Biochem J. 1978 Jun 1;171(3):759–765. doi: 10.1042/bj1710759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bossard M. J., Tomaszek T. A., Thompson S. K., Amegadzie B. Y., Hanning C. R., Jones C., Kurdyla J. T., McNulty D. E., Drake F. H., Gowen M. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996 May 24;271(21):12517–12524. doi: 10.1074/jbc.271.21.12517. [DOI] [PubMed] [Google Scholar]
  3. Fosang A. J., Neame P. J., Last K., Hardingham T. E., Murphy G., Hamilton J. A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992 Sep 25;267(27):19470–19474. [PubMed] [Google Scholar]
  4. Fox T., de Miguel E., Mort J. S., Storer A. C. Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry. 1992 Dec 22;31(50):12571–12576. doi: 10.1021/bi00165a005. [DOI] [PubMed] [Google Scholar]
  5. Hasnain S., Hirama T., Tam A., Mort J. S. Characterization of recombinant rat cathepsin B and nonglycosylated mutants expressed in yeast. New insights into the pH dependence of cathepsin B-catalyzed hydrolyses. J Biol Chem. 1992 Mar 5;267(7):4713–4721. [PubMed] [Google Scholar]
  6. Illy C., Quraishi O., Wang J., Purisima E., Vernet T., Mort J. S. Role of the occluding loop in cathepsin B activity. J Biol Chem. 1997 Jan 10;272(2):1197–1202. doi: 10.1074/jbc.272.2.1197. [DOI] [PubMed] [Google Scholar]
  7. Kuhelj R., Dolinar M., Pungercar J., Turk V. The preparation of catalytically active human cathepsin B from its precursor expressed in Escherichia coli in the form of inclusion bodies. Eur J Biochem. 1995 Apr 15;229(2):533–539. doi: 10.1111/j.1432-1033.1995.0533k.x. [DOI] [PubMed] [Google Scholar]
  8. Martel-Pelletier J., Cloutier J. M., Pelletier J. P. Cathepsin B and cysteine protease inhibitors in human osteoarthritis. J Orthop Res. 1990 May;8(3):336–344. doi: 10.1002/jor.1100080305. [DOI] [PubMed] [Google Scholar]
  9. Nägler D. K., Storer A. C., Portaro F. C., Carmona E., Juliano L., Ménard R. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. Biochemistry. 1997 Oct 14;36(41):12608–12615. doi: 10.1021/bi971264+. [DOI] [PubMed] [Google Scholar]
  10. Ren W. P., Fridman R., Zabrecky J. R., Morris L. D., Day N. A., Sloane B. F. Expression of functional recombinant human procathepsin B in mammalian cells. Biochem J. 1996 Nov 1;319(Pt 3):793–800. doi: 10.1042/bj3190793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rich D. H., Brown M. A., Barrett A. J. Purification of cathepsin B by a new form of affinity chromatography. Biochem J. 1986 May 1;235(3):731–734. doi: 10.1042/bj2350731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sivaraman J., Coloumbe R., Magny M. C., Mason P., Mort J. S., Cygler M. Crystallization of rat procathepsin B. Acta Crystallogr D Biol Crystallogr. 1996 Jul 1;52(Pt 4):874–875. doi: 10.1107/S0907444996001801. [DOI] [PubMed] [Google Scholar]
  13. Sloane B. F. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1990 Apr;1(2):137–152. [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES